Jasper Therapeutics, Inc.
JSPR · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $83 | $65 | $312 |
| - Cash | $51 | $40 | $49 | $72 |
| + Debt | $0 | $2 | $3 | $2 |
| Enterprise Value | – | $46 | $18 | $242 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$19 | -$27 | -$22 | -$25 |
| % Margin | – | – | – | – |
| Net Income | -$19 | -$27 | -$21 | -$24 |
| % Margin | – | – | – | – |
| EPS Diluted | -1.13 | -1.74 | -1.41 | -1.62 |
| % Growth | 35.1% | -23.4% | 13% | – |
| Operating Cash Flow | -$17 | -$15 | -$23 | -$21 |
| Capital Expenditures | $0 | -$0 | $0 | -$0 |
| Free Cash Flow | -$17 | -$15 | -$23 | -$21 |